Literature DB >> 31882469

Clinical Significance of Ubiquitin-associated Protein 2-like in Patients With Uterine Cervical Cancer.

Kosuke Yoshida1, Hiroaki Kajiyama2, Eri Inami3, Satoshi Tamauchi1, Yoshiki Ikeda1, Nobuhisa Yoshikawa1, Kimihiro Nishino1, Fumi Utsumi4, Kaoru Niimi1, Shiro Suzuki1, Kiyosumi Shibata4, Akihiro Nawa3, Fumitaka Kikkawa1.   

Abstract

BACKGROUND: Ubiquitin-associated protein 2-like (UBAP2L) has been demonstrated to be associated with the progression of multiple types of cancer. However, the function of UBAP2L in uterine cervical cancer remains unclear.
MATERIALS AND METHODS: Between 2005 and 2015, 84 patients who underwent surgery were included in this study. The patients were stratified into two groups on the basis of immunohistochemical staining for UBAP2L, and survival analysis was performed. Moreover, loss-of-function analysis was performed using the cervical cancer cell lines CaSki and SiHa.
RESULTS: Based on immunohistochemistry, the overall survival in patients with low UBAP2L expression was significantly longer than that of those with high UBAP2L expression (p=0.045). The in vitro experiment revealed that knockdown of UBAP2L remarkably inhibited cell proliferation in both live cell imaging and the MTS assay.
CONCLUSION: Patients with high UBAP2L expression had unfavorable prognosis and UBAP2L appears to play an important role in proliferation. Copyright
© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Cervical cancer; RNA interference; prognostic factor; proliferation; ubiquitin-associated protein 2-like

Mesh:

Substances:

Year:  2020        PMID: 31882469      PMCID: PMC6984086          DOI: 10.21873/invivo.11751

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.155


  25 in total

1.  Stress granules.

Authors:  Paul Anderson; Nancy Kedersha
Journal:  Curr Biol       Date:  2009-05-26       Impact factor: 10.834

Review 2.  Cytoplasmic stress granules: Dynamic modulators of cell signaling and disease.

Authors:  Hicham Mahboubi; Ursula Stochaj
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2017-01-15       Impact factor: 5.187

3.  Proteasome inhibitors for cancer therapy.

Authors:  Mohamed Iqbal; Patricia A Messina McLaughlin; Derek Dunn; Satish Mallya; Jean Husten; Mark A Ator; Sankar Chatterjee
Journal:  Bioorg Med Chem       Date:  2012-02-11       Impact factor: 3.641

4.  UBAP2L is amplified in a large subset of human lung adenocarcinoma and is critical for epithelial lung cell identity and tumor metastasis.

Authors:  Romain Aucagne; Simon Girard; Nadine Mayotte; Bernhard Lehnertz; Stéphane Lopes-Paciencia; Patrick Gendron; Geneviève Boucher; Jalila Chagraoui; Guy Sauvageau
Journal:  FASEB J       Date:  2017-07-28       Impact factor: 5.191

5.  Proteomic characterization of aggregating proteins after the inhibition of the ubiquitin proteasome system.

Authors:  Inga B Wilde; Maria Brack; Jason M Winget; Thibault Mayor
Journal:  J Proteome Res       Date:  2011-02-07       Impact factor: 4.466

6.  A post-recurrence survival-predicting indicator for cervical cancer from the analysis of 165 patients who developed recurrence.

Authors:  Kosuke Yoshida; Hiroaki Kajiyama; Fumi Utsumi; Kaoru Niimi; Jun Sakata; Shiro Suzuki; Kiyosumi Shibata; Fumitaka Kikkawa
Journal:  Mol Clin Oncol       Date:  2017-12-08

Review 7.  Cervical cancer.

Authors:  Steven E Waggoner
Journal:  Lancet       Date:  2003-06-28       Impact factor: 79.321

Review 8.  Targeting the ubiquitin-proteasome system for cancer therapy.

Authors:  Yili Yang; Jirouta Kitagaki; Honghe Wang; De-Xing Hou; Alan O Perantoni
Journal:  Cancer Sci       Date:  2008-11-24       Impact factor: 6.716

9.  Downregulation of ubiquitin-associated protein 2-like with a short hairpin RNA inhibits human glioma cell growth in vitro.

Authors:  Bing Zhao; Gang Zong; Yongsheng Xie; Jia Li; Hongliang Wang; Erbao Bian
Journal:  Int J Mol Med       Date:  2015-08-24       Impact factor: 4.101

10.  UBAP2L silencing inhibits cell proliferation and G2/M phase transition in breast cancer.

Authors:  Jing He; Yuanping Chen; Lu Cai; Zelei Li; Xiaoqing Guo
Journal:  Breast Cancer       Date:  2017-12-01       Impact factor: 4.239

View more
  3 in total

Review 1.  Ubiquitin Binding Protein 2-Like (UBAP2L): is it so NICE After All?

Authors:  Lucile Guerber; Evanthia Pangou; Izabela Sumara
Journal:  Front Cell Dev Biol       Date:  2022-06-20

Review 2.  Revisiting the Concept of Stress in the Prognosis of Solid Tumors: A Role for Stress Granules Proteins?

Authors:  Anaïs Aulas; Pascal Finetti; Shawn M Lyons; François Bertucci; Daniel Birnbaum; Claire Acquaviva; Emilie Mamessier
Journal:  Cancers (Basel)       Date:  2020-09-01       Impact factor: 6.639

3.  Prediction of early recurrence and response to adjuvant Sorafenib for hepatocellular carcinoma after resection.

Authors:  Liming Zheng; Xi Gu; Guojun Zheng; Xin Li; Meifang He; Longgen Liu; Xike Zhou
Journal:  PeerJ       Date:  2021-11-26       Impact factor: 2.984

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.